{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:26:54Z","timestamp":1790616414455,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates antitumor immunity and direct killing of CD27+ tumor cells in animal models. This first-in-human, dose-escalation, and expansion study evaluated varlilumab in patients with hematologic malignancies. Primary objectives were to assess safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. In a 3 + 3 dose-escalation design, 30 patients with B-cell (n = 25) or T-cell (n = 5) malignancies received varlilumab (0.1, 0.3, 1, 3, or 10 mg\/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles, depending on tumor response). In an expansion cohort, 4 additional patients with Hodgkin lymphoma received varlilumab at 0.3 mg\/kg every 3 weeks (4 doses per cycle, up to 5 cycles). No dose-limiting toxicities were observed. Treatment-related adverse events, generally grade 1 to 2, included fatigue, decreased appetite, anemia, diarrhea, and headache. Exposure was linear and dose-proportional across dose groups and resulted in increases in proinflammatory cytokines and soluble CD27. One patient with stage IV Hodgkin lymphoma experienced a complete response and remained in remission at &amp;gt;33 months with no further anticancer therapy. These data support further investigation of varlilumab for hematologic malignancies, particularly in combination approaches targeting nonredundant immune regulating pathways. This trial was registered at www.clinicaltrials.gov as #NCT01460134.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001079","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T19:04:19Z","timestamp":1588878259000},"page":"1917-1926","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":71,"title":["Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies"],"prefix":"10.1182","volume":"4","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":false,"given":"Ian","family":"Flinn","sequence":"first","affiliation":[{"name":"Center for Blood Cancer, Sarah Cannon Research Institute, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-9001","authenticated-orcid":false,"given":"Matthew H.","family":"Taylor","sequence":"first","affiliation":[{"name":"Franz Cancer Center, Providence Portland Medical Center, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branimir I.","family":"Sikic","sequence":"first","affiliation":[{"name":"Clinical and Translational Research Unit, Stanford Cancer Institute, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua","family":"Brody","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Mount Sinai Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nemunaitis","sequence":"first","affiliation":[{"name":"Division of Hematology, University of Toledo College of Medicine and Life Sciences, Toledo, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew","family":"Feldman","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Hawthorne","sequence":"first","affiliation":[{"name":"Celldex Therapeutics, Inc., Hampton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Rawls","sequence":"first","affiliation":[{"name":"Celldex Therapeutics, Inc., Hampton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1757-4230","authenticated-orcid":false,"given":"Tibor","family":"Keler","sequence":"first","affiliation":[{"name":"Celldex Therapeutics, Inc., Hampton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Yellin","sequence":"first","affiliation":[{"name":"Celldex Therapeutics, Inc., Hampton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"issue":"11","key":"2020050715041240300_B1","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.V82.11.3430.3430","article-title":"Expression and release of CD27 in human B-cell malignancies","volume":"82","author":"van Oers","year":"1993","journal-title":"Blood"},{"issue":"9","key":"2020050715041240300_B2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1080\/1042819021000006385","article-title":"CD148 and CD27 are expressed in B cell lymphomas derived from both memory and na\u00efve B cells","volume":"43","author":"Dong","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020050715041240300_B3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.20030916","article-title":"CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool","volume":"198","author":"Hendriks","year":"2003","journal-title":"J Exp Med"},{"issue":"5","key":"2020050715041240300_B4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/80877","article-title":"CD27 is required for generation and long-term maintenance of T cell immunity","volume":"1","author":"Hendriks","year":"2000","journal-title":"Nat Immunol"},{"issue":"10","key":"2020050715041240300_B5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/eji.1830251017","article-title":"CD27\/CD70 interaction directly drives B cell IgG and IgM synthesis","volume":"25","author":"Agematsu","year":"1995","journal-title":"Eur J Immunol"},{"issue":"24","key":"2020050715041240300_B6","doi-asserted-by":"crossref","first-page":"11249","DOI":"10.1073\/pnas.92.24.11249","article-title":"CD27-CD70 interactions regulate B-cell activation by T cells","volume":"92","author":"Kobata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2020050715041240300_B7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood.V91.1.173","article-title":"Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27\/CD70 interaction","volume":"91","author":"Agematsu","year":"1998","journal-title":"Blood"},{"issue":"9","key":"2020050715041240300_B8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1084\/jem.188.9.1679","article-title":"Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells","volume":"188","author":"Klein","year":"1998","journal-title":"J Exp Med"},{"issue":"2","key":"2020050715041240300_B9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2567.1996.tb00017.x","article-title":"CD27\/CD70 interaction directly induces natural killer cell killing activity","volume":"88","author":"Yang","year":"1996","journal-title":"Immunology"},{"issue":"14","key":"2020050715041240300_B10","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Claus","year":"2012","journal-title":"Cancer Res"},{"issue":"14","key":"2020050715041240300_B11","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-11-3308","article-title":"Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia","volume":"18","author":"Vitale","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2020050715041240300_B12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-015-0080-2","article-title":"Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab","volume":"3","author":"Ramakrishna","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"8","key":"2020050715041240300_B13","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.4049\/jimmunol.1300409","article-title":"Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice","volume":"191","author":"He","year":"2013","journal-title":"J Immunol"},{"issue":"12","key":"2020050715041240300_B14","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.4049\/jimmunol.1700606","article-title":"CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy","volume":"199","author":"Wasiuk","year":"2017","journal-title":"J Immunol"},{"issue":"18","key":"2020050715041240300_B15","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020050715041240300_B16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2020050715041240300_B17","first-page":"582","article-title":"Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies","volume":"6","author":"Korman","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"issue":"10","key":"2020050715041240300_B18","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2020050715041240300_B19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"35","key":"2020050715041240300_B20","doi-asserted-by":"crossref","first-page":"57197","DOI":"10.18632\/oncotarget.11084","article-title":"The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance","volume":"7","author":"Alidzanovic","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"2020050715041240300_B21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-17-3057","article-title":"PD-1 blockade and CD27 stimulation activate distinct transcriptional programs that synergize for CD8+ T-cell-driven antitumor immunity","volume":"24","author":"Buchan","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020050715041240300_B22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccell.2017.11.001","article-title":"Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment","volume":"32","author":"Turaj","year":"2017","journal-title":"Cancer Cell"},{"issue":"22","key":"2020050715041240300_B23","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V128.22.1848.1848","article-title":"CDX-1140, a novel agonist CD40 antibody with potent anti-lymphoma activity","volume":"128","author":"He","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020050715041240300_B24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00262-018-2267-0","article-title":"Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy","volume":"68","author":"Vitale","year":"2019","journal-title":"Cancer Immunol Immunother"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/9\/1917\/1727863\/advancesadv2019001079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/9\/1917\/1727863\/advancesadv2019001079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T19:04:33Z","timestamp":1588878273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/9\/1917\/454777\/Safety-and-activity-of-varlilumab-a-novel-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001079","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}